CXCL9 and lung cancer: CXCL9/10-DC vaccination mitigated tumor growth in three additional syngeneic murine lung cancer models, including high TMB KrasG12DTp53−/−-3M (KP-3M; 22.1 mutations/Mb), low TMB KrasG12D (LKR13; 0.7 mutations/Mb),28 and bronchoalveolar carcinoma (L1C2) (Figures 2D–2F).